HITMAN-PC Phase 1 Results: Hydroxychloroquine + SUBA-Itraconazole Stabilizes Biochemical Prostate Cancer Relapse

/in , , /by

The HITMAN-PC trial represents a targeted metabolic approach to managing biochemical relapse in prostate cancer, combining hydroxychloroquine (HCQ) and SUBA-itraconazole (SI) to disrupt lysosomal function and cholesterol trafficking in hormone-sensitive disease. In this phase 1 dose-escalation study, 11 men (median age 73, baseline PSA 4.4 ng/mL, PSA doubling time 5.3 months) received fixed SI at […]

Read more

BG-C0979: Pioneering Phase 1 Trial Targets ADAM9 in Advanced Solid Tumors, Including CRPC

/in , , , , /by

A first-in-human Phase 1 clinical trial is underway to evaluate BG-C0979, a novel antibody-drug conjugate (ADC) designed for adults with advanced solid tumors. This open-label study focuses on assessing the drug’s safety, tolerability, pharmacokinetics, and early signs of antitumor activity through dose escalation and potential expansion phases. BG-C0979 targets ADAM9, a disintegrin and metalloproteinase enzyme […]

Read more

Alliance A222001 Phase 2 Trial: Oxybutynin Looks Promising for Hot Flashes in Men Under ADT

/in , , , , /by

The Alliance A222001 study, published in the Journal of Clinical Oncology in January 2026, found that oxybutynin, a drug typically used to treat overactive bladder, significantly reduces hot flashes in men receiving androgen-deprivation therapy (ADT), with improvements occurring within the first week of treatment and sustained throughout the study period. The findings could reshape how […]

Read more

Metabolic Blockade in Prostate Cancer: Repurposing SGLT2 Inhibitors as Dual Antitumor and Cardio-Protective Therapy

/in , , /by

SGLT2 inhibitors, familiar as diabetes medications like dapagliflozin and canagliflozin, show promise against prostate cancer (and other solid tumors) through targeted metabolic disruption that exploits cancer cells’ addiction to glucose. Prostate tumors frequently overexpress SGLT2 transporters, enabling excessive glucose uptake that fuels the Warburg effect, where cancer cells convert glucose to lactate even in oxygen-rich […]

Read more

Phase 1 Trial for RAD 402, Terbium Based Radioligand for Metastatic or Locally Advanced or Prostate Cancer

/in , , , , /by

Australian Human Research Ethics Committee has approved the initiation of a first‑in‑human Phase 1 therapeutic trial of RAD 402, a KLK3 (PSA)‑targeting monoclonal antibody labeled with terbium‑161 for patients with metastatic or locally advanced prostate cancer. The approval positions the program to begin site activation and enrollment in Australia, marking a notable milestone for a […]

Read more

Low‑Dose Naltrexone for ADT‑Related Fatigue in Prostate Cancer

/in , , , , /by

A new trial will test whether nightly low‑dose naltrexone (3 mg) reduces fatigue in men with prostate cancer receiving androgen‑deprivation therapy (ADT), while concurrently profiling mitochondrial, inflammatory, and oxidative stress pathways that may drive cancer‑related fatigue in this setting. The single‑arm University of Arkansas study plans to enroll 60 men over 30 months, using FACIT‑F […]

Read more

Final OS Data from EMBARK Phase 3 Trial: Enzalutamide With ADT for Men at Risk of BRPC

/in , , /by

Data from the phase 3 EMBARK trial, combining enzalutamide with standard hormone therapy, recently published in The New England Journal of Medicine and presented at the 2025 European Society for Medical Oncology (ESMO) Congress, reveal that this combination reduces the risk of death by more than 40% over eight years compared to hormone therapy alone. […]

Read more

Positive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation

/in , , /by
Read more